Clinical trials: HPV
Patient Adherence
Evaluation of a mHealth Intervention to Increase Adherence to Triage of Self-collected HPV+ Women (ATICA Project)
Background: Cervical cancer is one of the leading causes of cancer death among women worldwide, with more than 85% of cases occurring in low- and middle-income countries.
- Trial name
- ATICA (NCT03478397)
- Testing
- Multicomponent mHealth Intervention
- Where
- Argentina
- Volunteers
- 5,389 people
- Sponsor
- Centro de Estudio de Estado y Sociedad
Inflammatory Bowel Disease, Uterine Cervical Dysplasia
Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease
The Gardasil vaccine, a vaccine targeted towards the human papillomavirus (HPV), has been shown to prevent the transmission of several strains of HPV in young women.
- Trial name
- NCT01034358
- Testing
- Human Papillomavirus Vaccine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell
Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions
Background: Human papillomavirus (HPV) can cause vulvar high-grade squamous intraepithelial lesions (HSIL). Sometimes, this can become cancer. Researchers want to see if T cell therapy can treat vulvar HSIL.
- Conditions
- Squamous Lntraepithelial Lesions of Vulva, Neoplasms, Squamous Cell, Vulvar HSIL
- Trial name
- NCT03937791
- Testing
- E7 T Cell Receptor (TCR)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Cervical Dysplasia
Acceptability and Efficacy of Self-sampling for Cervical Cancer Screening: A Pilot Study
In Singapore, the current cervical cancer screening uptake among women in Singapore has remained at low 50% since its introduction in 2004.
- Conditions
- Cervical Cancer, Cervical Dysplasia, Human Papillomavirus Infection
- Trial name
- NCT03813576
- Testing
- Self-collected HPV vaginal swab
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC
This study is the first clinical study in PD-1 resistant patients with head and neck squamous cell carcinoma with drugs targeting EGFR signaling pathway combined with CDK4/6 inhibitors, which explores the new combination…
- Trial name
- NCT05721443
- Testing
- Dalpiciclib+cetuximab
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Locally Advanced Cervical Cancer, Prognostic Biomarker
Evaluation of Persistent Infection by Oncogenic Human Papillomavirus (HPV) in Patients Treated for Cervical Carcinoma and Its Relation to Prognostic Factors
Cervical cancer is strongly associated with HPV infection, yet current post-treatment follow-up relies on cytology and imaging, which have limited accuracy, particularly after radiotherapy.
- Trial name
- ANIHTA (NCT07600515)
- Volunteers
- 100 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Papillomavirus Infections
Diversity Analysis of Vaginal Microbiota on Women With High-risk Human Papillomavirus Infection
Since other genital infections enhance HIV susceptibility by inducing inflammation, the investigators study the relationship between the vaginal microbiota composition and the risk of HPV infection, cervical cytological…
- Trial name
- NCT03548740
- Testing
- Human Papillomavirus
- Where
- China
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Human Papilloma Virus (HPV) Circulating Tumor DNA (ctDNA) in Cervical Cancer
This study collects blood samples to determine if the DNA of HPV that causes cervical cancer can be detected in patients with cervical cancer that is new (primary), has come back (recurrent), or has spread to other places in the…
- Conditions
- Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Infiltrating Cervical Carcinoma, Metastatic Cervical Carcinoma
- Trial name
- NCT04574635
- Testing
- Biospecimen Collection
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Cervical Intraepithelial Neoplasia
A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia
The primary objective of this study is to determine pilot safety and efficacy data for a topical formulation of EM-1421 applied to the cervix of patients with CIN 1, 2, or 3.
- Trial name
- NCT00154089
- Testing
- EM-1421
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Erimos Pharmaceuticals
HPV Knowledge
AI Chatbot Education for Improving HPV Knowledge Among University Students
Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide and is associated with several cancers. Adequate knowledge about HPV and vaccination remains limited among university students.
- Trial name
- AIHPV (NCT07684378)
- Testing
- AI Chatbot-Based Education, Standard Written Education
- Where
- Cyprus
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Near East University, Turkey
Human Papillomavirus Infection
HPV Vaccination in Women With Cystic Fibrosis
The main risk factor for the development of cervical lesions is human papillomavirus (HPV) infection. Vaccination against human papillomavirus, which is offered to all girls aged 11 to 14, and catching up to girls aged 15 to 19…
- Trial name
- VACCIN-HPV-MUC (NCT03265743)
- Testing
- Self-report Written Questionnaire
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Hospices Civils de Lyon
HPV
Self-sampling for Human Papillomavirus (HPV) Among Patients Receiving Colposcopy
This study seeks to compare the accuracy and acceptability of HPV testing self-sampling kit and standard clinician-sampling for HPV testing.
- Trial name
- NCT04585243
- Testing
- Evalyn Brush
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Milton S. Hershey Medical Center
HPV InfectioN, HPV-Related Carcinoma
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
A total of 18000 healthy women aged 18-45 years old were divided into three age groups: 18-26 years old, 27-35 years old, and 36-45 years old. The experimental group and the placebo group were randomly assigned in a ratio of 1:1.
- Trial name
- NCT06041061
- Testing
- Recombinant 14-Valent Human Papillomavirus Vaccine（Insect Cell）
- Where
- 5 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Condylomata Acuminata
Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile
This is an observational study looking at the characteristics of patients consulting for genital warts in the first semester 2010 at the public sexual health clinic of Valparaiso, Chile.
- Trial name
- NCT01483794
- Where
- 2 sites in Chile
- Volunteers
- 60 people
- Sponsor
- Universidad de Valparaiso
Human Papilloma Virus Related Cervical Carcinoma
The Women's Screening and Self-Testing Program (PROMETA) Study
This proposal directly addresses the ability to safely scale-up a Screen-Triage-Treat approach to cervical cancer screening. The investigators propose to capitalize on a pool of screen-eligible women accessing routine care within…
- Trial name
- PROMETA (NCT06810739)
- Testing
- HPV DNA testing be self-collected vaginal swab
- Where
- Mozambique
- Volunteers
- 8,445 people
- Sponsor
- Tulane University
Cervical Intraepithelial Neoplasia Grade 1 (CIN 1)
Diagnostic and Prognostic Value of p16INK4a Expression in Low Grade Squamous Intraepithelial Lesions of the Cervix.
P16INK4a has recently been described as a surrogate marker for HR-HPV associated squamous and glandular intraepithelial lesions of the cervix.
- Trial name
- NCT00343213
- Testing
- colposcopy
- Where
- 3 sites in France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma
This phase II trial studies how well radiation therapy and cisplatin with or without cetuximab works in treating patients with human papillomavirus (HPV) positive, KRAS-variant stage III-IV oropharyngeal squamous cell carcinoma.
- Conditions
- Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04106362
- Testing
- Cetuximab, Cisplatin, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Jonsson Comprehensive Cancer Center
HPV
The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children…
- Trial name
- NCT04722822
- Testing
- (Intervention) Recommending HPV vaccine for patients 9-10 years of age, (Control) Recommending HPV vaccine for patients 11-12 years of age
- Where
- 2 sites in United States
- Volunteers
- 62,272 people
- Sponsor
- University of Colorado, Denver
Penile Squamous Cell Carcinoma (PSCC)
Trial Using Gilotrif for Advanced Penile Squamous Cell Carcinoma
Penile squamous cell carcinoma (PSCC) is a highly aggressive and relatively rare disease. Supportive evidence for the value of systemic therapy does not exist for this disease and there are no agents currently approved by…
- Trial name
- NCT02541903
- Testing
- Gilotrif
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Alabama at Birmingham
Infections, Papillomavirus
Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old
The current study evaluates the immunogenicity and safety in 4-6 years old female subjects (experimental group) receiving Cervarix according to a 2-dose schedule (Month 0, 6), as compared to 4-6 years old female subjects (control…
- Trial name
- NCT01627561
- Testing
- Cervarix, Priorix, Infanrix
- Where
- 4 sites in Colombia, Mexico and 1 more
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.